Disease · MONDO_0000878

cytomegalovirus retinitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cytomegalovirus retinitis. Diseases, record MONDO_0000878. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000878

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cytomegalovirus retinitis; Open Targets
Open Targets ID: MONDO_0000878; Open Targets
Other names: Cytomegaloviral Retinitis, Cytomegalovirus caused retinitis, Retinitis, Cytomegaloviral; Open Targets
Disease Ontology: DOID:0080160; Disease Ontology
MeSH: D017726; MeSH
NCI Thesaurus: C50521; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 19 drugs, from DailyMed and TTD; Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GANCICLOVIR	CHEMBL182	Small molecule	Approval	DailyMed	27	25	25	Drugs and targets
CIDOFOVIR	CHEMBL5314375	Small molecule	Approval	DailyMed	13	9	9	Drugs and targets
FOMIVIRSEN SODIUM	CHEMBL1201512	Oligonucleotide	Approval	TTD	5	4	4	Drugs and targets
FOSCARNET SODIUM	CHEMBL754	Small molecule	Approval	DailyMed and TTD	5	3	3	Drugs and targets
VALGANCICLOVIR HYDROCHLORIDE	CHEMBL1200454	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
FOMIVIRSEN	CHEMBL1201688	Oligonucleotide	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
GANCICLOVIR SODIUM	CHEMBL1200850	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
FOSCARNET	CHEMBL666	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
SARGRAMOSTIM	CHEMBL1201670	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
VALGANCICLOVIR	CHEMBL1201314	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets22

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
POLA1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/5426	Drugs and targets
POLE2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/5427	Drugs and targets
POLE3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/54107	Drugs and targets
PRIM1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Unknown	https://conductscience.org/library/genes/5557	Drugs and targets

1 to 10 of 22

See all 22 targets

Trials48

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00000134	Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)	Phase 3	279	2015-09-14	HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis	FOSCARNET, GANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00000136	Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)	Phase 3	234	2015-10-22	HIV Infections, Cytomegalovirus Retinitis	FOSCARNET, GANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00000135	Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)	Phase 2/3	209	2015-11-17	HIV Infections, Cytomegalovirus Retinitis	SEVIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT00000142	Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)	Phase 2/3	64	2015-11-17	HIV Infections, CMV Cytomegalovirus Retinitis	CIDOFOVIR	Its record names the disease	ClinicalTrials.gov
NCT00000143	Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)	Phase 3	61	2016-03-14	Cytomegalovirus Retinitis, HIV Infections	CIDOFOVIR, GANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00017784	Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection	Phase 3	500		Cytomegalovirus Retinitis, HIV Infections	VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00000766	CMV Retinitis Retreatment Trial	Phase 2	300		Cytomegalovirus Retinitis, HIV Infections	FOSCARNET, GANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00000836	A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)	Phase 2	300		Cytomegalovirus Retinitis, HIV Infections	SEVIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT00000894	Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis	Phase 4	300		Cytomegalovirus Retinitis, HIV Infections	CIDOFOVIR, GANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00002330	A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS	Not applicable	280		Cytomegalovirus Retinitis, HIV Infections	GANCICLOVIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 48

See all 48 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Foscarnet vs Ganciclovir: Mortality	107 of 107	127 of 127	234	NCT00000136	Trial comparisons
Foscarnet vs Ganciclovir: serious adverse events	60 of 107	73 of 127	234	NCT00000136	Trial comparisons
MSL-109 vs Placebo: serious adverse events	0 of 104	0 of 105	209	NCT00000135	Trial comparisons
Ganciclovir Implant and Oral Ganciclovir vs Cidofovir IV (Intravenous): Survival	31 of 31	30 of 30	61	NCT00000143	Trial comparisons
Ganciclovir Implant and Oral Ganciclovir vs Cidofovir IV (Intravenous): serious adverse events	0 of 31	0 of 30	61	NCT00000143	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23665863	RESULT	1	PubMed
15498605	RESULT	1	PubMed
12559647	RESULT	1	PubMed
12232843	RESULT	1	PubMed
11919489	RESULT	1	PubMed
9400786	RESULT	1	PubMed
31042791	DERIVED	2	PubMed
30526535	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000878

GET https://conductscience.org/api/diseases/v1/MONDO_0000878/targets?page=2

API reference For AI assistants